NCT00227760View on ClinicalTrials.gov

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Recurrent Renal Cell CarcinomaStage IV Renal Cell Cancer
Interventions
DRUG

Cediranib Maleate

Given PO

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (6)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1Y 4E9

The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00227760 - Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter